Private equity firm Cinven has announced a strategic investment in Regenity Biosciences, a health technology company that operates as a portfolio company of Linden Capital Partners. The investment marks Cinven's entry into the growing health tech sector, though financial terms of the deal were not disclosed in the brief announcement.

Regenity Biosciences specializes in developing innovative biotechnology solutions, though specific details about its product pipeline or therapeutic focus were not provided in the source material. The company's existing relationship with Linden Capital Partners suggests it has already attracted private equity interest and likely demonstrated promising growth potential in the competitive health tech landscape.

This investment by Cinven represents a strategic move to capitalize on the expanding health technology market, which has seen increased investor attention following the pandemic-driven acceleration of digital health adoption. While the exact size and structure of Cinven's investment remain undisclosed, the deal underscores continued private equity appetite for health tech innovations with scalable business models.